Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.
- DOI
- 10.1186/s12933-025-02752-2
- Published
- 2025 May 15
- Container
- Cardiovascular diabetology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12933-025-02752-2,
title = {Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.},
author = {Quist SW and van Schoonhoven AV and Bakker SJL and Pochopień M and Postma MJ and van Loon JMT and Paulissen JHJ},
year = {2025},
journal = {Cardiovascular diabetology},
doi = {10.1186/s12933-025-02752-2},
url = {https://doi.org/10.1186/s12933-025-02752-2}
}RIS
TY - JOUR TI - Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. AU - Quist SW AU - van Schoonhoven AV AU - Bakker SJL AU - Pochopień M AU - Postma MJ AU - van Loon JMT AU - Paulissen JHJ PY - 2025 JO - Cardiovascular diabetology DO - 10.1186/s12933-025-02752-2 UR - https://doi.org/10.1186/s12933-025-02752-2 ER -
APA
SW, Q., AV, V. S., SJL, B., M, P., MJ, P., JMT, V. L., & JHJ, P. (2025). Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.. Cardiovascular diabetology. https://doi.org/10.1186/s12933-025-02752-2
Source records
- pubmed · retrieved 2026-09-26T21:49:22.186Z